Statistics on Biotechnology Use  
Results by sector of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.133;564;212;358;
%Companies according to biotechnology used: Genetic code;32;42;22;20;
%Companies according to biotechnology used: Functional units;41;48;40;30;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;27;33;24;19;
%Companies according to biotechnology used: Bioprocesses;48;41;47;60;
%Companies according to biotechnology used: Sub-cellular organisms;8;11;8;4;
%Companies according to biotechnology used: Bio-computing;21;31;13;11;
%Companies according to biotechnology used: Nanobiotechnology;14;18;16;7;
%Companies according to biotechnology used: Other;13;13;15;12;
%Company by field(s) of ultimate application of biotechnology use: Human Health;50;70;42;23;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;19;21;18;17;
%Company by field(s) of ultimate application of biotechnology use: Food products;29;22;30;40;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;21;19;25;23;
%Company by field(s) of ultimate application of biotechnology use: Environment;13;11;20;10;
%Company by field(s) of ultimate application of biotechnology use: Industry;13;13;18;12;
Personnel in R&D in biotechnology (no. of persons);10.706;5.968;1.806;2.932;
Personnel in R&D in biotechnology (no. of persons): Researchers;6.227;3.765;994;1.467;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;4.479;2.202;812;1.464;
Personnel in R&D in biotechnology (no. of persons): women;5.795;3.402;884;1.510;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;3.269;2.049;503;717;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;2.527;1.353;381;793;
Personnel in R&D in biotechnology (FTE);7.716,4;4.708,3;1.165,8;1.842,3;
Personnel in R&D in biotechnology (FTE): Researchers;4.603,1;2.952,5;690,5;960,1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;3.113,3;1.755,8;475,3;882,2;
Personnel in R&D in biotechnology (FTE): women;4.292,9;2.666;584,9;1.042;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2.446,4;1.592,2;352,1;502,1;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.846,5;1.073,7;232,8;539,9;
Internal expenditure on R&D (thousands of euros);616.053;401.754;86.676;127.622;
1) By nature of the expense: Current expenses;574.245;371.873;81.601;120.772;
1.1) Remuneration to researchers;221.741;145.148;33.906;42.688;
1.2) Remuneration to technicians and assistants;102.464;53.306;17.155;32.002;
1.3) Other current expenses;250.041;173.419;30.540;46.082;
2) By nature of the expense: Capital expenses;41.808;29.882;5.075;6.851;
2.1) Land and buildings;5.359;3.592;486;1.281;
2.2) Equipment and instruments;29.489;20.787;4.073;4.630;
2.3) Acquisition of specific R+D software;2.306;1.549;139;618;
2.4) Otros productos de propiedad intelectual específicos para I+D;4.654;3.955;377;322;
1) By origin of the funds: National funds;511.960;311.167;76.048;124.744;
1.1) Own funds;382.335;232.410;47.954;101.970;
1.2) From companies;45.024;25.073;10.783;9.168;
1.3) Public Administration funds;72.387;45.317;16.642;10.428;
1.4) From Universities;363;363;0;.;
1.5) From non profit private institutions;11.851;8.005;669;3.178;
1) By origin of the funds: Foreign funds;104.093;90.587;10.628;2.879;
2.1) From EU programmes;21.825;13.669;5.814;2.342;
2.2) Other foreign funds;82.269;76.918;4.813;537;
Purchase of R&D services in biotechnology (thousands of euros);144.342;91.533;26.448;26.360;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;70.458;43.549;11.885;15.023;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;73.885;47.984;14.563;11.337;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;48;57;46;35;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13;12;14;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;15;15;16;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;12;12;18;11;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;16;18;21;9;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;16;20;18;9;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;16;17;18;11;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;36;40;43;26;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;49;56;47;39;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;18;17;24;16;
% Companies that have requested biotechnology patents;16;24;8;7;
Number of patents requested;633;474;71;88;
% Companies with income of an international origin related to biotechnological activities;24;32,7;15,5;15,2;
% Turnover representing income of an international origin related to biotechnological activities;1,4;9;0,1;2,6;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;57,3;35,5;37,3;77,6;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;42,7;64,5;62,7;22,4;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;82,3;91,3;80,2;74,3;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;16,5;7,1;.;25,6;
% Income of an international origin related with activities according to the classification: Operating source abroad;1;1,1;19,6;0,1;
% Income of an international origin related with activities according to the classification: Other;0,3;0,6;0,2;0;
Notas:

.
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute